|
Getting your Trinity Audio player ready...
|
Patients with generalized anxiety disorder (GAD) exhibit sustained improvements in their symptoms following the use of cannabis products, according to data published in the journal Psychopharmacology.
British investigators assessed the safety and efficacy of plant-derived cannabis products (either oils, flower, or a combination of both) in over 300 patients enrolled in the UK Medical Cannabis Registry. All of the participants possessed a doctor’s authorization to access cannabis products. (Since 2018, specialists have been permitted to prescribe cannabis-based medicinal products to patients unresponsive to conventional medications.) Authors assessed the efficacy of cannabis at one, three, and six months.
Researchers reported improvements in patients’ anxiety, sleep quality, and overall quality of life at each time point assessed.
“Prescription of CBMPs [cannabis-based medicinal products] in those with GAD is associated with clinically significant improvements in anxiety with an acceptable safety profile in a real-world setting,” they concluded.
The findings are consistent with those of other studies documenting both short-term and sustained reductions in anxiety following patients’ use of either cannabis or CBD products.
Prior studies assessing the use of cannabis products in patients enrolled in the UK registry have similarly reported them to be effective and well-tolerated among those suffering from chronic pain, post-traumatic stress, depression, migraine, inflammatory bowel disease, and other afflictions.
Full text of the study, “Clinical outcome data of anxiety patients treated with cannabis-based medicinal products in the United Kingdom: A cohort study from the UK Medical Cannabis Registry,” appears in Psychopharmacology.
